Merck & Co., Inc. (MRK)
Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 bln
Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday.
Merck (MRK) Advances While Market Declines: Some Information for Investors
Merck (MRK) reachead $106.64 at the closing of the latest trading day, reflecting a +0.28% change compared to its last close.
Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?
We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates billions of dollars in revenues.
Gilead, MRK Report Data From Investigational Combination Study for HIV
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
Merck RSV jab has the potential to protect infants
Merck & Co Inc's (NYSE:MRK, ETR:6MK) experimental treatment for respiratory syncytial virus (RSV) has shown positive results in a mid- to late-stage trial, moving the company closer to seeking regulatory approval. The treatment, clesrovimab, aims to protect infants from RSV, a leading cause of hospitalizations in newborns and responsible for hundreds of infant deaths annually.
Merck's RSV antibody for infants shows over 60% efficacy in mid-late-stage study
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing respiratory syncytial virus (RSV) infections in infants.
Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
Merck said its experimental treatment designed to protect infants from respiratory syncytial virus showed positive results in a mid- to late-stage trial. The pharmaceutical giant could emerge as a new competitor in the market for treatments against RSV, which causes hundreds of infant deaths each year.
Merck (MRK) Rises As Market Takes a Dip: Key Facts
The latest trading day saw Merck (MRK) settling at $111.53, representing a +1.68% change from its previous close.
2 Incredibly Cheap Big Pharma Stocks to Buy Now
There's doubtlessly some coming uncertainty for both, but the prices are right.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Merck Is At Support And Should Go Higher (Technical Analysis)
Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level that is likely to hold. Keytruda remains a key revenue driver, with potential for continued growth and extended patent protection through a subcutaneous formulation. Strategic acquisitions are broadening Merck's pipeline and should reduce its reliance on Keytruda, despite the short-term profit impacts.
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
